Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 20708687 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Karyo R, et al. (2010) Identification of eukaryotic elongation factor-2 as a novel cellular target of lithium and glycogen synthase kinase-3. Mol Cell Neurosci 45, 449-55 20708687
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T57-p - eEF-2 (human) ▲
Orthologous residues
eEF‑2 (human): T57‑p, eEF‑2 (mouse): T57‑p, eEF‑2 (rat): T57‑p, eEF‑2 (rabbit): T56‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  neuroblastoma
 Relevant cell lines - cell types - tissues:  SH-SY5Y (neural crest)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
lithium decrease
serum withdrawal lithium augment treatment-induced decrease low serum
glucose starvation lithium augment treatment-induced decrease glucose-depleted medium
valproic acid no change compared to control
carbamazepine no change compared to control
IP(3) no change compared to control
lithium IP(3) decrease
peptide inhibitor increase L803-mts, [N-Myristol-GKEAPPAPPQS(p)P]
TDZD-8 increase
BIO increase BIO-6
SB216763 increase
GSK3B (human) decrease
GSK3A (human) decrease
lithium SB216763 inhibit treatment-induced increase
lithium TDZD-8 inhibit treatment-induced increase

S366-p - eEF2K (human) ▲
Orthologous residues
eEF2K (human): S366‑p, eEF2K (mouse): S365‑p, eEF2K (rat): S365‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  neuroblastoma
 Relevant cell lines - cell types - tissues:  SH-SY5Y (neural crest)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose increase high glucose
low glucose decrease

S21-p - GSK3A (human) ▲
Orthologous residues
GSK3A (human): S21‑p, GSK3A (mouse): S21‑p, GSK3A (rat): S21‑p, GSK3A (cow): S21‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  neuroblastoma
 Relevant cell lines - cell types - tissues:  SH-SY5Y (neural crest)
 Cellular systems studied:  cell lines
 Species studied:  human

S9-p - GSK3B (human) ▲
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S3‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  neuroblastoma
 Relevant cell lines - cell types - tissues:  SH-SY5Y (neural crest)
 Cellular systems studied:  cell lines
 Species studied:  human

S240-p - S6 (human) ▲
Orthologous residues
S6 (human): S240‑p, S6 (mouse): S240‑p, S6 (rat): S240‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  neuroblastoma
 Relevant cell lines - cell types - tissues:  SH-SY5Y (neural crest)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SB216763 decrease
lithium increase
GSK3A (human) increase
GSK3B (human) increase

S244-p - S6 (human) ▲
Orthologous residues
S6 (human): S244‑p, S6 (mouse): S244‑p, S6 (rat): S244‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  neuroblastoma
 Relevant cell lines - cell types - tissues:  SH-SY5Y (neural crest)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SB216763 decrease
lithium increase
GSK3A (human) increase
GSK3B (human) increase

T57-p - eEF-2 (mouse) ▲
Orthologous residues
eEF‑2 (human): T57‑p, eEF‑2 (mouse): T57‑p, eEF‑2 (rat): T57‑p, eEF‑2 (rabbit): T56‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  'brain, hippocampus'
 Cellular systems studied:  tissue
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
lithium decrease

S9-p - GSK3B (mouse) ▲
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S3‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  'brain, hippocampus'
 Cellular systems studied:  tissue
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
lithium increase

S240-p - S6 (mouse) ▲
Orthologous residues
S6 (human): S240‑p, S6 (mouse): S240‑p, S6 (rat): S240‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  'brain, hippocampus'
 Cellular systems studied:  tissue
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
lithium increase

S244-p - S6 (mouse) ▲
Orthologous residues
S6 (human): S244‑p, S6 (mouse): S244‑p, S6 (rat): S244‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  'brain, hippocampus'
 Cellular systems studied:  tissue
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
lithium increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.